MAP2K7 and head and neck squamous cell carcinoma: However, in research on six PIK3CA-amplified, PI3K inhibition-resistant HNSCC cell lines, dual inhibition of PI3K and MEK (by HS-173 and trametinib, respectively) displayed synergistic responses only in UM-SCC-69 and UM-SCC-108 cells [113].